IP Verse

Eliglustat (Genz 112638) As Inhibitor Of Glucosylceramide Synthase For Use In A Method Of Treating Fabry'S Or Gaucher'S Disease, The Method Comprising Adjusting The Individual Therapeutical Dose To The P-450 Metabolism Of The Patient - EP3133070

The patent EP3133070 was granted to Genzyme on Aug 14, 2019. The application was originally filed on Nov 24, 2010 under application number EP16175117A. The patent is currently recorded with a legal status of "Revoked".

EP3133070

GENZYME
Application Number
EP16175117A
Filing Date
Nov 24, 2010
Status
Revoked
May 19, 2025
Grant Date
Aug 14, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCAREMay 14, 2020BRAND MURRAY FULLERADMISSIBLE
HETERO LABSMay 14, 2020ZBM PATENTS APSADMISSIBLE
TEVA PHARMACEUTICALSMay 13, 2020D YOUNGADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS5916911
DESCRIPTIONUS5945442
DESCRIPTIONUS5952370
DESCRIPTIONUS6030995
DESCRIPTIONUS6051598
DESCRIPTIONUS7253185
OPPOSITIONWO03008399
OPPOSITIONWO2008150486
SEARCHWO2008150486

Non-Patent Literature (NPL) Citations (60) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- A. ABE ET AL., J. CLIN. INV., (2000), vol. 105, pages 1563 - 1571
DESCRIPTION- B.N. AMES, METHODS ENZYMOL., (1966), vol. 8, pages 115 - 118
DESCRIPTION- G.A. GRABOWSKI ET AL., ANN. INT. MED., (1995), vol. 122, pages 33 - 39
DESCRIPTION- HAKOMORI, S., "New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy", CANCER CELLS, (1991), vol. 3, pages 461 - 470
DESCRIPTION- H.S. OVERKLEEFT ET AL., J. BIOL. CHEM., (1998), vol. 273, pages 26522 - 26527
DESCRIPTION- H. ZHAO ET AL., DIABETES, (2007), vol. 56, pages 1341 - 1349
DESCRIPTION- INOKUCHI, J. ET AL., "Antitumor Activity in Mice of an Inhibitor of Glycosphingolipid Biosynthesis", CANCER LETT., (1987), vol. 38, pages 23 - 30
DESCRIPTION- INOKUCHI, J. ET AL., "Inhibition of Experimental Metastasis of Murine Lewis Long Carcinoma by an Inhibitor of Glucosylceramide Synthase and its Possible Mechanism of Action", CANCER RES., (1990), vol. 50, pages 6731 - 6737
DESCRIPTION- K.A. MCEACHEM ET AL., MOL. GENET. METAB., (2007), vol. 91, pages 259 - 267
DESCRIPTION- K. MCEACHERN ET AL., J. GENE MED., (2006), vol. 8, pages 719 - 729
DESCRIPTION- K. MCEACHERN ET AL., J. GENE. MED., (2006), vol. 8, pages 719 - 729
DESCRIPTION- MCELROY, "CYP2D6 Genotyping as an Alternative to Phenotyping for Determination of Metabolic Status in a Clinical Trial Setting", AAPS PHARMSI, vol. 2, no. 4, (2000), page 33, URL: http://www.pharmsci.org/
DESCRIPTION- S.M. VAN PATTEN ET AL., GLYCOBIOLOGY, (2007), vol. 17, pages 467 - 478
DESCRIPTION- S.P.F. MILLER ET AL., J. LAB. CLIN. MED., (1996), vol. 127, pages 353 - 358
DESCRIPTION- SVENSSON, M. ET AL., "Epithelial Glucosphingolipid Expression as a Determinant of Bacterial Adherence and Cytokine Production", INFECT, AND IMMUN., (1994), vol. 62, pages 4404 - 4410
DESCRIPTION- T. DOERING ET AL., J. BIOL. CHEM., (1999), vol. 274, pages 11038 - 11045
DESCRIPTION- T. DOERING, J. BIOL. CHEM., (1999), vol. 274, pages 11038 - 11045
DESCRIPTION- The CYP450 Gene Family and Drug Metabolism, HOFFMANN LA ROCHE LTD.
DESCRIPTION- U. ANDERSSON ET AL., BIOCHEM. PHARM., (2000), vol. 59, pages 821 - 829
DESCRIPTION- U. ANDERSSON ET AL., BIOCHEM. PHARM., (2004), vol. 67, pages 697 - 705
DESCRIPTION- WANG, AM ET AL., AM. J. HUM. GENET., (1996), vol. 59, page A208
DESCRIPTION- Y-H. XU ET AL., AM. J. PATHOL., (2003), vol. 163, pages 2093 - 2101
DESCRIPTION- Y.-H. XU ET AL., AM. J. PATHOL., (2003), vol. 163, pages 2093 - 2101
DESCRIPTION- ZICHE, M. ET AL., "Angiogenesis Can Be Stimulated or Repressed in In Vivo by a Change in GM3 :GD3 Ganglioside Ratio", LAB. INVEST., (1992), vol. 67, pages 711 - 715
DESCRIPTION- ZIEGLER, RJ ET AL., MOLEC. THER., (2007), vol. 15, no. 3, pages 492 - 500
OPPOSITION- Anonymous, "A Study of Genz-112638 in Patients With Gaucher Disease(ENGAGE) (NCT00891202)", ClinicalTrials.gov Archive, (20091103), ClinicalTrials.gov Archive, URL: https://clinicaltrials.gov/archive/NCT00891202/2009_11_03, (20170601), XP055378017
OPPOSITION- anonymous, "A Study of Genz-112638 in Patients With Gaucher Disease Who Have Been Stabilized on Cerezyme (ENCORE)", Clinicaltrials.gov Study NCT00943111, (20091105), URL: https://clinicaltrials.gov/ct2/history/NCT00943111?V_5=View#StudyPageTop, XP055378019
OPPOSITION- Anonymous, "A Study of Genz-112638 in Patients With Gaucher Disease Who Have Been Stabilized on Cerezyme (NCT00943111)", ClinicalTrials.gov Study NCT00943111, (20091105), ClinicalTrials.gov Study NCT00943111, URL: https://clinicaltrials.gov/archive/NCT00943111/2009_11_05, (20170601), XP055378019
OPPOSITION- anonymous, "Drug Metabolism and Pharmacokinetics - an overview", Eur Pharm Rev, (20091212), URL: https://www.europeanpharmaceuticalreview.com/article/655/drug-metabolism-and-pharmacokinetics-an-overview/#:~:text=Pharmacodynamics%20(PD)%2C%20which%20studies,include%20PK%20and%20PD%20objectives.&text=Pharmacokinetics%20(PK)%2C%20is%20the,body%20deals%20with%20the%20drug., XP055704210
OPPOSITION- anonymous, "Study of Genzyme Oral Compound for Gaucher Disease Meets Primary Endpoint", Sanofi Press Release, (20090220), URL: https://www.sanofigenzyme.com/en/about-us/newsroom/archive/2009/2009-02-20-01-45-00, XP055704207
OPPOSITION- BELLE D et al., "Genetic Factors in Drug Metabolism", Amer Family Physician, (20080601), vol. 77, no. 11, pages 1553 - 1560, XP055704212
OPPOSITION- E LUKINA et al., "GENZ-112638, AN INVESTIGATIONAL ORAL THERAPY FOR GAUCHERDISEASE TYPE 1: PHASE 2 CLINICAL TRIAL RESULTS AFTER ONE YEAR OF TREATMENT", Haematologica, (20090000), vol. 94, no. s2, page 41, XP055704206
OPPOSITION- E LUKINA et al., "Latest Data on Genz-112638, an Investigational Oral Therapy for Type 1 Gaucher Disease:Phase II Clinical Trial Results After 1 Year of Treatment", Clinical Therapeutics, (20090000), vol. 31, no. C, pages S194 - S195, XP026786231
OPPOSITION- Ioannides Costas, "Substrate Binding and Selectivity", Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and other Xenobiotics, RSC Publishing, (20080101), pages 15 - 24, XP055739882
OPPOSITION- Ioannides Zanger, "The CYP2D Subfamily", Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and other Xenobiotics, RSC Publisher, (20080101), pages 255 - 264, XP055739887
OPPOSITION- P Wijnen, Et Al, "Review article: the prevalence and clinical relevance ofcytochrome P450 polymorphisms", Alimentary Pharmacology & Therapeutics, (20070101), vol. 26, no. 2, pages 211 - 219, XP055739758
OPPOSITION- "Substrate reduction therapy", S TOMLINSON et al., Mechanism of Disease - An Introduction to Clinical Science. 2nd ed., Cambridge University Press, (20080000), page 63; 64, XP055704205
OPPOSITION- "The CYP450 Gene Family and Drug Metabolism", Background Information, Roche Diagnostics
OPPOSITION- Timothy M Cox, "Other stratagems for treating Gaucher's disease", mechanisms of Disease, Cambridge Medicine, (20080101), pages 62 - 63, XP055739869
OPPOSITION- US Department of health and human services food and drug, "Guidance for Industry, Pharmacogenomic Dada Submissions", Guidance for Industry, Pharmacogenomic Dada Submissions, (20050300), pages 1 - 29
OPPOSITION- Van Schaik Ron, "Dose Adjustments Based on Pharmacogenetics of CYP450 Enzymes", The Communications and Publications Division (CPD) of the IFCC, (20080403), vol. 19, no. 1, pages 42 - 47, XP055704214
OPPOSITION- ULRICH M. ZANGER et al., "Cytochrome P450 2D6: Overview and Update on Pharmacology, Genetics", Biochemistry , Naunyn-Schmiedeberg's Archives of Pharmacology, (20040000), vol. 369, doi:10.1007/s00210-003-0832-2, pages 23 - 37, XP002555967
OPPOSITION- McEachern, K.A. Fung, J. Komarnitsky, S. Siegel, C.S. Chuang, W.L. Hutto, E. Shayman, J.A. Grabowski, G.A. Aerts, J.M.F.G. Cheng, S.H. Copeland, D.P. Marshall, J., "A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease", Molecular Genetics and Metabolism, Academic Press, AMSTERDAM, NL, AMSTERDAM, NL, (20070531), vol. 91, no. 3, doi:10.1016/j.ymgme.2007.04.001, ISSN 1096-7192, pages 259 - 267, XP022102856
OPPOSITION- MCEACHERN KERRY ANNE ET AL, "A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease", Molecular Genetics and Metabolism, Academic Press, AMSTERDAM, NL, AMSTERDAM, NL, (20070701), vol. 91, no. 3, doi:10.1016/J.YMGME.2007.04.001, ISSN 1096-7192, pages 259 - 267, XP002617211
OPPOSITION- McEACHEM K et al., "24 Genz-112638: A novel orally available ceramide-based inhibitor of glucosylceramide synthase for treating Gaucher disease", Mol Gen & Met, (20071120), vol. 92, no. 4, page S17, XP022354774
OPPOSITION- McEachern, K. Siegel, C. Fung, J. Chuang, W.L. Hutto, E. Sung, C. Blankstein, L. Peterschmitt, M.J. Grabowski, G.A. Copeland, D.P. Cheng, S.H. Marshall, J., "24 Genz-112638: A novel orally available ceramide-based inhibitor of glucosylceramide synthase for treating Gaucher disease", Molecular Genetics and Metabolism, Academic Press, AMSTERDAM, NL, AMSTERDAM, NL, (20071120), vol. 92, no. 4, doi:10.1016/j.ymgme.2007.08.029, ISSN 1096-7192, page 17, XP022354774
OPPOSITION- Peterschmitt, J. Lukina, E. Watman, N. Banikazemi, M. Iastrebner, M. Rosenbaum, H. Zimran, A. Arreguin, E.A. O'Brien, F. Smith, S. Puga, A.C., "73. Preliminary results of a phase II clinical trial of Genz-112638 in patients with type I Gaucher disease", Molecular Genetics and Metabolism, Academic Press, AMSTERDAM, NL, AMSTERDAM, NL, (20080114), vol. 93, no. 2, doi:10.1016/j.ymgme.2007.10.085, ISSN 1096-7192, pages 32 - 33, XP022420706
OPPOSITION- PETERSCHMITT J et al., "102. Genz-112638, an investigational oral treatment for D1 Gaucher disease type 1: Preliminary Phase 2 clinical trial results", Molecular Genetics And Metabolism, AMSTERDAM, NL, (20090114), vol. 96, no. 2, doi:10.1016/j.ymgme.2008.11.103, page S34, XP025772035
OPPOSITION- Peterschmitt, J.et al, "102. Genz-112638, an investigational oral treatment for Gaucher disease type 1: Preliminary Phase 2 clinical trial results", Molecular Genetics and Metabolism, Academic Press, AMSTERDAM, NL, AMSTERDAM, NL, (20090201), vol. 96, no. 2, doi:10.1016/j.ymgme.2008.11.103, ISSN 1096-7192, page S34, XP025772035
OPPOSITION- PETERSCHMITT J et al., "102. Genz-112638, an investigational oral treatment for Gaucher disease type 1: Preliminary Phase 2 clinical trial results", Mol Gen & Met, (20090201), vol. 96, no. 2, page S34, XP025772035
OPPOSITION- GAEDIGK A et al., "The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype", Clinical Pharmacology and Therapeutics, (20080200), vol. 83, no. 2, pages 234 - 242, XP055704225
OPPOSITION- SHARP CF et al., "CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure", The Pharmacogenomics Journal, (20090601), vol. 9, no. 3, pages 175 - 184, XP008134361
OPPOSITION- BERTILSON L. et al., "Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs", Br J Clin Pharmacol., (20020200), vol. 53, no. 2, doi:10.1046/j.0306-5251.2001.01548.x, pages 111 - 22, XP055381924
OPPOSITION- ZHOU S et al., "Polymorphism of human cytochrome P450 enzymes and its clinical impact", Drug Met Rev, (20090000), vol. 41, no. 2, pages 89 - 295, XP055704222
OPPOSITION- MCELROY et al., "CYP2D6 Genotyping as an Alternative to Phenotyping for Determination of Metabolic Status in a Clinical Trial Setting", AAPS Pharmsi, (20000000), vol. 2, no. 4, doi:10.1208/ps020433, XP002251960
OPPOSITION- J.A. SHAYMAN, "Eliglustat tartrate", Drugs Of The Future, (20100801), vol. 35, no. 8, doi:10.1358/dof.2010.035.08.1505566, pages 613 - 620, XP002757375
OPPOSITION- TERRY D BUTTERS, "Pharmacotherapeutic Strategies Using Small Molecules for the Treatment of Glycolipid Lysosomal Storage Disorders", Expert Opinion on Pharmacotherapy, (20070000), vol. 8, no. 4, doi:10.1517/14656566.8.4.427, pages 427 - 435, XP009131356
OPPOSITION- BOZINA N et al., "Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk", Arh Hg Rada Toksikol, (20090601), vol. 60, no. 2, pages 217 - 242, XP055704217
SEARCH- PETERSCHMITT J ET AL, "102. Genz-112638, an investigational oral treatment for Gaucher disease type 1: Preliminary Phase 2 clinical trial results", MOLECULAR GENETICS AND METABOLISM, ACADEMIC PRESS, AMSTERDAM, NL, vol. 96, no. 2, doi:10.1016/J.YMGME.2008.11.103, ISSN 1096-7192, (20090201), page S34, (20090113), XP025772035 [X] 1-12 * abstract * [I] 1-12
SEARCH- J.A. SHAYMAN, "Eliglustat tartrate", DRUGS OF THE FUTURE, (20100101), vol. 35, no. 8, doi:10.1358/dof.2010.035.08.1505566, ISSN 0377-8282, pages 613 - 620, XP055198504 [XP] 1-12 * page 613; title; chemical name; chemical structure; summary * * page 614; scheme 1 * * page 616; right-hand column; pharmacokinetics and metabolism; 2nd paragraph * * page 617; clinical studies; left-hand column; 1st paragraph; right-hand column; 2nd and 3rd paragraph * [I] 1-12

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents